Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Eli Lilly & Co. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Current Ratio since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Eli Lilly & Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The solvency position, as indicated by the presented metrics, exhibits fluctuations over the five-year period. Generally, leverage ratios increased through 2023 before decreasing in the final two years. Coverage ratios experienced a similar pattern, declining in 2023 before improving significantly in 2024 and 2025.
- Debt Levels
- Debt to equity, with and without the inclusion of operating lease liabilities, increased from 2022 to 2023, reaching peaks of 2.34 and 2.44 respectively. This suggests a greater reliance on debt financing during that period. However, both ratios decreased in 2024 and 2025, returning towards levels observed in 2021 and 2022. A similar trend is observed in debt to capital ratios, both including and excluding operating lease liabilities, peaking in 2023 and then declining. Debt to assets ratios also followed this pattern, increasing to 0.43 in 2024 before decreasing to 0.38 in 2025.
- Leverage
- Financial leverage increased from 4.65 in 2022 to 5.94 in 2023, indicating a higher proportion of assets financed by debt. This was followed by a decrease to 4.24 in 2025, suggesting a reduction in the company’s financial risk. The trend mirrors the changes observed in the debt-related ratios.
- Coverage Ratios
- Interest coverage decreased from 21.53 in 2022 to 14.49 in 2023, indicating a reduced ability to meet interest obligations with earnings. However, a substantial improvement occurred in 2024 and 2025, with the ratio reaching 29.75 in the latter year. Fixed charge coverage followed a similar trajectory, declining in 2023 to 10.98 and then increasing significantly to 29.75 in 2025. This suggests a strengthening capacity to cover all fixed financing costs.
In summary, the period between 2022 and 2023 appears to have involved increased debt utilization, which subsequently decreased. The coverage ratios indicate a temporary weakening in the ability to service fixed charges, followed by a strong recovery and improvement in the final two years of the observed period.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term borrowings and current maturities of long-term debt | ||||||
| Long-term debt, excluding current maturities | ||||||
| Total debt | ||||||
| Total Eli Lilly and Company shareholders’ equity | ||||||
| Solvency Ratio | ||||||
| Debt to equity1 | ||||||
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Equity, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Equity, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity = Total debt ÷ Total Eli Lilly and Company shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio exhibits a fluctuating pattern over the five-year period. Initially, the ratio decreased before increasing substantially, then stabilizing and decreasing again.
- Debt to Equity Trend (2021-2025)
- In 2021, the debt to equity ratio stood at 1.88. A decrease was observed in 2022, with the ratio falling to 1.52. This indicates a relative increase in shareholders’ equity compared to total debt during this period.
- However, 2023 saw a significant increase in the ratio, reaching 2.34. This rise suggests a greater reliance on debt financing relative to equity. The ratio continued to climb in 2024, reaching 2.37, indicating a further increase in financial leverage.
- By 2025, the debt to equity ratio decreased to 1.60. This reduction suggests a rebalancing of the capital structure, with shareholders’ equity growing at a faster rate than total debt. The substantial increase in shareholders’ equity in 2025 appears to be the primary driver of this decline.
Total debt increased consistently throughout the period, rising from US$16,885 million in 2021 to US$42,503 million in 2025. Total shareholders’ equity also increased, but at a slower pace until 2025, when it experienced a significant jump from US$14,192 million to US$26,535 million.
The observed fluctuations in the debt to equity ratio suggest changes in the company’s financing strategy and capital structure. The increases in the ratio in 2023 and 2024 indicate a period of increased financial leverage, while the decrease in 2025 suggests a move towards a more balanced capital structure.
Debt to Equity (including Operating Lease Liability)
Eli Lilly & Co., debt to equity (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term borrowings and current maturities of long-term debt | ||||||
| Long-term debt, excluding current maturities | ||||||
| Total debt | ||||||
| Operating lease liabilities, current portion (included in Other current liabilities) | ||||||
| Operating lease liabilities, noncurrent portion (included in Other noncurrent liabilities) | ||||||
| Total debt (including operating lease liability) | ||||||
| Total Eli Lilly and Company shareholders’ equity | ||||||
| Solvency Ratio | ||||||
| Debt to equity (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Equity (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Equity (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Eli Lilly and Company shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio, including operating lease liability, demonstrates a fluctuating pattern over the five-year period. Initially, the ratio decreased before increasing and then decreasing again, suggesting shifts in the company’s capital structure and financing strategies.
- Total Debt Trend
- Total debt, inclusive of operating lease liabilities, exhibited an increasing trend throughout the observed period. Starting at US$17,570 million in 2021, it rose to US$43,865 million by 2025. The most substantial increases occurred between 2022 and 2023, and again between 2023 and 2024, indicating a growing reliance on debt financing.
- Shareholders’ Equity Trend
- Total shareholders’ equity also increased over the period, though not at the same rate as total debt. Beginning at US$8,979 million in 2021, it reached US$26,535 million in 2025. The largest increase in shareholders’ equity occurred between 2024 and 2025, potentially reflecting retained earnings or new equity issuance.
- Debt to Equity Ratio Analysis
- In 2021, the debt to equity ratio stood at 1.96. This decreased to 1.59 in 2022, suggesting a strengthening equity position relative to debt. However, the ratio increased to 2.44 in 2023 and remained relatively stable at 2.45 in 2024, indicating a higher level of financial leverage. By 2025, the ratio decreased to 1.65, driven by a larger increase in shareholders’ equity compared to the increase in total debt. This final decrease suggests a partial rebalancing of the capital structure.
The observed fluctuations in the debt to equity ratio warrant further investigation to understand the underlying drivers, such as specific financing activities, investment decisions, and profitability trends. The increasing trend in total debt, coupled with periods of higher leverage, should be monitored to assess potential financial risks.
Debt to Capital
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term borrowings and current maturities of long-term debt | ||||||
| Long-term debt, excluding current maturities | ||||||
| Total debt | ||||||
| Total Eli Lilly and Company shareholders’ equity | ||||||
| Total capital | ||||||
| Solvency Ratio | ||||||
| Debt to capital1 | ||||||
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Capital, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Capital, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The Debt to Capital ratio exhibits a fluctuating pattern over the five-year period. Initially, the ratio decreased before stabilizing and then declining again. Total debt and total capital both increased consistently throughout the period, but at differing rates, influencing the ratio’s movement.
- Overall Trend
- The Debt to Capital ratio began at 0.65 in 2021, decreased to 0.60 in 2022, and then increased to 0.70 in 2023. The ratio remained stable at 0.70 in 2024 before decreasing to 0.62 in 2025. This suggests an initial period of reduced reliance on debt financing relative to capital, followed by increased leverage, and a subsequent reduction in leverage towards the end of the observed period.
- Debt and Capital Growth
- Total debt increased from US$16,885 million in 2021 to US$42,503 million in 2025, representing a substantial overall increase. Total capital also increased, moving from US$25,864 million in 2021 to US$69,038 million in 2025. The rate of increase in debt appears to have outpaced the rate of increase in capital in 2023 and 2024, contributing to the peak in the Debt to Capital ratio during those years.
- Ratio Stabilization and Decline
- The stabilization of the ratio at 0.70 in 2024 indicates a period where debt and capital grew proportionally. The subsequent decrease to 0.62 in 2025 suggests that capital growth exceeded debt growth during that year, leading to a lower level of debt relative to the company’s capital structure.
The observed fluctuations in the Debt to Capital ratio warrant further investigation into the specific financing activities and capital investments undertaken during each period to fully understand the drivers behind these changes.
Debt to Capital (including Operating Lease Liability)
Eli Lilly & Co., debt to capital (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term borrowings and current maturities of long-term debt | ||||||
| Long-term debt, excluding current maturities | ||||||
| Total debt | ||||||
| Operating lease liabilities, current portion (included in Other current liabilities) | ||||||
| Operating lease liabilities, noncurrent portion (included in Other noncurrent liabilities) | ||||||
| Total debt (including operating lease liability) | ||||||
| Total Eli Lilly and Company shareholders’ equity | ||||||
| Total capital (including operating lease liability) | ||||||
| Solvency Ratio | ||||||
| Debt to capital (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Capital (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Capital (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
The Debt to Capital ratio, inclusive of operating lease liabilities, demonstrates a fluctuating pattern over the five-year period. Initially, the ratio decreased before stabilizing and then declining again. Total debt and total capital both increased consistently throughout the period, but at differing rates, influencing the ratio’s movement.
- Initial Decline (2021-2022)
- From 2021 to 2022, the Debt to Capital ratio decreased from 0.66 to 0.61. This reduction occurred alongside a decrease in total debt, from US$17,570 million to US$16,967 million, while total capital experienced a modest increase, moving from US$26,550 million to US$27,617 million. This suggests a relative strengthening of the capital structure during this period.
- Stabilization and Increase (2022-2023)
- The ratio stabilized at 0.71 in both 2023 and 2024. While total debt increased significantly, from US$16,967 million to US$34,791 million, total capital grew at a faster rate, rising from US$27,617 million to US$48,983 million. The proportional increase in capital offset the rise in debt, maintaining the ratio at the same level. This indicates a continued ability to fund growth with both debt and equity.
- Subsequent Decline (2024-2025)
- In 2025, the Debt to Capital ratio decreased to 0.62. This decline coincided with a further increase in total capital, reaching US$70,400 million, while total debt continued to rise, albeit at a slower pace, to US$43,865 million. The larger increase in capital relative to debt resulted in a lower ratio, suggesting improved solvency.
- Overall Trend
- Despite substantial increases in both total debt and total capital over the five-year period, the Debt to Capital ratio did not exhibit a consistent upward trend. The ratio initially decreased, then stabilized, and finally decreased again, indicating a dynamic relationship between debt and capital financing. The company appears capable of managing its debt levels relative to its capital base, with capital growth often outpacing debt accumulation.
Debt to Assets
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term borrowings and current maturities of long-term debt | ||||||
| Long-term debt, excluding current maturities | ||||||
| Total debt | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets1 | ||||||
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Assets, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Assets, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The Debt to Assets ratio exhibits a fluctuating pattern over the five-year period. Initially, the ratio decreased before increasing and then decreasing again, suggesting shifts in the company’s financial leverage.
- Overall Trend
- The Debt to Assets ratio began at 0.35 in 2021, decreased to 0.33 in 2022, and then increased consistently to 0.43 in 2024. A slight decrease to 0.38 was observed in 2025. This indicates an initial period of reduced reliance on debt financing, followed by increased borrowing, and a subsequent stabilization.
- Year-over-Year Changes
- From 2021 to 2022, the ratio decreased, indicating a reduction in debt relative to assets. However, from 2022 to 2023, the ratio increased from 0.33 to 0.39, suggesting a rise in debt levels. The most significant increase occurred between 2023 and 2024, with the ratio climbing to 0.43. The final year observed a slight decrease, but remained elevated compared to earlier periods.
- Debt and Asset Growth
- Total debt increased substantially throughout the period, rising from US$16,885 million in 2021 to US$42,503 million in 2025. Total assets also increased, but at a varying rate, growing from US$48,806 million in 2021 to US$112,476 million in 2025. The faster growth of debt between 2023 and 2024 contributed to the peak in the Debt to Assets ratio during that time.
The observed increases in the Debt to Assets ratio suggest a growing reliance on debt financing. While asset growth accompanied the debt increase, the ratio’s fluctuations warrant continued monitoring to assess the company’s long-term solvency and financial risk.
Debt to Assets (including Operating Lease Liability)
Eli Lilly & Co., debt to assets (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term borrowings and current maturities of long-term debt | ||||||
| Long-term debt, excluding current maturities | ||||||
| Total debt | ||||||
| Operating lease liabilities, current portion (included in Other current liabilities) | ||||||
| Operating lease liabilities, noncurrent portion (included in Other noncurrent liabilities) | ||||||
| Total debt (including operating lease liability) | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Assets (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Assets (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The Debt to Assets ratio, including operating lease liability, demonstrates a fluctuating pattern over the five-year period. Initially, the ratio decreased before increasing and then decreasing again, suggesting evolving financial leverage.
- Overall Trend
- From 2021 to 2023, the ratio increased from 0.36 to 0.41. This indicates a growing proportion of assets financed by debt. The ratio then continued to rise to 0.44 in 2024, representing the highest level observed during the period. Finally, in 2025, the ratio decreased to 0.39, signaling a reduction in financial leverage.
- Debt and Asset Growth
- Total debt, including operating lease liability, increased consistently throughout the period, rising from US$17,570 million in 2021 to US$43,865 million in 2025. Total assets also increased substantially, moving from US$48,806 million in 2021 to US$112,476 million in 2025. The differing rates of growth in debt and assets contribute to the observed fluctuations in the Debt to Assets ratio.
- Ratio Fluctuations
- The initial decrease in the ratio from 2021 to 2022 suggests that asset growth outpaced debt growth during that time. However, from 2022 to 2024, debt growth exceeded asset growth, leading to an increase in the ratio. The subsequent decrease in 2025 indicates a rebalancing, with asset growth once again exceeding debt growth.
The observed trend suggests a period of increased reliance on debt financing followed by a partial reduction in that reliance. Continued monitoring of these figures is recommended to assess the long-term implications of these changes.
Financial Leverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Total assets | ||||||
| Total Eli Lilly and Company shareholders’ equity | ||||||
| Solvency Ratio | ||||||
| Financial leverage1 | ||||||
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Financial Leverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Financial Leverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Financial leverage = Total assets ÷ Total Eli Lilly and Company shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
An examination of the financial information reveals trends in the company’s financial leverage over a five-year period. Total assets increased consistently throughout the period, demonstrating substantial growth, particularly between 2023 and 2025. Simultaneously, total shareholders’ equity also increased, though at a slower pace than asset growth until 2025, when a significant rise is observed.
- Financial Leverage
- The financial leverage ratio exhibited a decreasing trend from 2021 to 2022, falling from 5.44 to 4.65. This suggests a reduction in the proportion of assets financed by debt or other liabilities during that year. However, the ratio increased again in 2023 to 5.94, indicating a renewed reliance on external financing relative to equity. A slight decrease to 5.55 was noted in 2024. Notably, 2025 saw a considerable decline in the financial leverage ratio to 4.24, the lowest value observed during the analyzed period. This decrease coincides with the largest increase in shareholders’ equity, suggesting a strengthening of the company’s financial position and a reduced dependence on financial leverage.
The observed pattern suggests a dynamic approach to capital structure management. While the company initially reduced its reliance on financial leverage, it subsequently increased it before ultimately decreasing it again in the most recent year. The substantial growth in both assets and equity in 2025 appears to have contributed to the most significant reduction in financial leverage, indicating a potentially more conservative financial strategy at the end of the period.
The increasing asset base, coupled with the fluctuating financial leverage ratio, warrants continued monitoring to assess the long-term implications for the company’s financial risk profile.
Interest Coverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense on borrowings | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Solvency Ratio | ||||||
| Interest coverage1 | ||||||
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Interest Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Interest Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
The interest coverage ratio demonstrates a generally positive trend over the observed period, though with some fluctuation. Earnings before interest and tax (EBIT) and interest expense on borrowings both influence this ratio, and their individual movements contribute to the observed patterns.
- Overall Trend
- The interest coverage ratio increased from 19.12 in 2021 to 21.53 in 2022, indicating an improved ability to meet interest obligations with earnings. A decrease to 14.49 was then observed in 2023, before recovering to 17.24 in 2024. The most significant increase occurred between 2024 and 2025, with the ratio reaching 29.75.
- EBIT Influence
- EBIT experienced an initial increase from US$6,495 million in 2021 to US$7,138 million in 2022, supporting the rise in the interest coverage ratio during that period. A slight decline in EBIT to US$7,040 million in 2023 coincided with the decrease in the interest coverage ratio. However, substantial growth in EBIT to US$13,461 million in 2024 and further to US$26,626 million in 2025 drove the significant improvements in the ratio during those years.
- Interest Expense Influence
- Interest expense on borrowings remained relatively stable between 2021 and 2023, fluctuating between US$332 million and US$486 million. An increase to US$781 million in 2024 and US$895 million in 2025 was observed. Despite these increases in interest expense, the substantial growth in EBIT more than offset the impact, resulting in a continued upward trend in the interest coverage ratio.
The increasing interest coverage ratio suggests a strengthening capacity to service debt obligations. The significant jump in 2025, driven by substantial EBIT growth, indicates a considerably improved financial position with respect to interest-bearing debt.
Fixed Charge Coverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense on borrowings | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Add: Lease expense for operating lease assets | ||||||
| Earnings before fixed charges and tax | ||||||
| Interest expense on borrowings | ||||||
| Lease expense for operating lease assets | ||||||
| Fixed charges | ||||||
| Solvency Ratio | ||||||
| Fixed charge coverage1 | ||||||
| Benchmarks | ||||||
| Fixed Charge Coverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Fixed Charge Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Fixed Charge Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
The company demonstrates a generally positive trend in its ability to meet fixed financial obligations, as indicated by its fixed charge coverage ratio. Earnings before fixed charges and tax, and fixed charges themselves, both exhibit fluctuations over the observed period, ultimately contributing to significant changes in the coverage ratio.
- Earnings Before Fixed Charges and Tax
- Earnings before fixed charges and tax increased from US$6,655 million in 2021 to US$7,287 million in 2022, representing a growth of approximately 9.5%. A slight decrease was then observed in 2023, falling to US$7,212 million. However, a substantial increase occurred in 2024, reaching US$13,671 million, followed by a further significant rise to US$26,626 million in 2025. This indicates a strong and accelerating improvement in profitability before accounting for fixed financing costs and income taxes.
- Fixed Charges
- Fixed charges decreased from US$499 million in 2021 to US$480 million in 2022. An increase was then noted in 2023, rising to US$657 million. This trend continued into 2024, with fixed charges reaching US$990 million, before decreasing slightly to US$895 million in 2025. While fluctuations are present, the overall increase from 2022 to 2024 suggests a potential increase in financing costs or similar fixed obligations.
- Fixed Charge Coverage
- The fixed charge coverage ratio began at 13.33 in 2021 and improved to 15.17 in 2022, reflecting the increase in earnings and decrease in fixed charges. A decline to 10.98 was observed in 2023, likely due to the slight decrease in earnings and increase in fixed charges. The ratio then rebounded to 13.81 in 2024, coinciding with the substantial increase in earnings. Finally, the ratio experienced a dramatic increase to 29.75 in 2025, driven by the continued growth in earnings and a slight decrease in fixed charges. This indicates a significantly strengthened ability to cover fixed obligations with earnings.
Overall, the company’s fixed charge coverage ratio demonstrates a positive trajectory, particularly in the later years of the period. The substantial increase in earnings before fixed charges and tax in 2024 and 2025 is the primary driver of this improvement, suggesting a strengthening financial position regarding its fixed financial commitments.